eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

3/2009
vol. 1
 
Share:
Share:

Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences

Ferenc Lakosi
,
Gergely Antal
,
Csaba Vandulek
,
Arpad Kovacs
,
Janos Pall
,
Istvan Rakasz
,
Istvan Kiss
,
Imre Repa
,
Peter Bogner

J Contemp Brachyther 2009; 1, 3: 190
Online publish date: 2009/10/08
Article file
Get citation
 
 
Purpose: To demonstrate the feasibility of transperineal open MR-guided HDR prostate brachytherapy and to present our initial clinical experiences.
Material and methods: Between 10.2007 and 05.2009, 17 patients with intermediate (n = 11) to high risk prostate (n = 6) cancer were treated with 46-60 Gy of 3D conformal external beam radiotherapy preceded and/or followed by an 8-10 Gy MR-guided HDR boost. For interventions an MR compatible custom-made device, coaxial needles and plastic catheters were used. The patients were placed in the right lateral decubitus position. Template reconstruction, trajectory planning, image guidance, contouring and treatment planning were directly based on MR images. For treatment planning geometric optimisation (n = 5) and anatomy based inverse planning w/wo graphical optimisation (n = 12) were used.
Results: The average dosimetric results for the target volume were the followings: V100: 94% (82-99), V150: 44% (37-64), V200: 18.8% (12-35), D90: 104.2% (89-122.8). D0.1cc and D1cc for the intraprostatic urethra and anterior rectal wall were 117.7% (89-141.2), 98.7% (64-122.9) and 76.9% (59.1-85.6), 65.1% (44.5-72). The average maximum dose for the inner rectal surface was 54.6% (39-64). For bulbo-membranousos urethra the mean D0.1cc parameter was 71.4% (52.6-98.6). The observed acute gastrointestinal (GI), genitourinary (GU) and toxicity (RTOG) were the followings: GI Gr. 0–1: 12 pts, Gr. 2: 5 pts; GU Gr. 0–1: 7 pts, Gr. 2: 10 pts. The mean and standard deviation of 100 plastic catheter displacements at 10-13 cm target depth was 2.2 mm ±1.3 mm. The average procedure time was 5.5 hours (4.5-7.5). Image quality was excellent for all cases.
Conclusions: Based on the initial experiences our method seems to be a promising approach for performing feasible, accurate, reliable and high-quality MR-guided prostate brachytherapy. Although the rate of acute toxicities is feasible, higher number of patients, additional follow-up is required to determine the long side effects and efficacy.
Copyright: © 2009 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.